Quotient Therapeutics’ Post

As various trends continue to shape what has been an eventful year for the biotech industry, Labiotech.eu compiled a list of the leading European biotech companies that have secured significant seed funding in the past year. These companies are channeling their resources into research and development (R&D) programs across a diverse range of therapeutic areas. One notable trend is the rise of artificial intelligence-enabled drug discovery startups. According to a report by Grand View Research, the global market for artificial intelligence in drug discovery was valued at approximately $1.5 billion in 2023, with projections indicating an annual growth rate of nearly 30% from 2024 to 2030. Here is a list of 10 European biotech companies poised to make a substantial impact in the biotech sector. Read the article to discover who these companies are. SpenglerFox Labiotech.eu #Spenglerfox #Labiotech #Startups #Biotech

Great insight from Labiotech.eu highlighting the rising EU startup Biotechs in 2024, highlighting a trend of increased AI-driven drug discovery startups. The market was valued at $1.5 billion and is projected to grow by nearly 30% annually from 2024 to 2030. #biotech #pharma #ai #drugdiscovery #startup

SparkBio, the biotechnology and healthcare-specialized accelerator operated by SparkLabs, a global accelerator (AC), has signed a memorandum of understanding (MOU) with Pohang City to establish a 'clinical specialized hospital'.

SparkBio, a biotechnology and healthcare-specialized accelerator operated by SparkLabs, a global accelerator (AC), announced on January 22 that it has signed a memorandum of understanding (MOU) with Pohang City on January 21 to establish a 'clinical specialized hospital'. The signing ceremony took place at the startup incubation center 'Maru 360' in Gangnam District, Seoul. Key participants included SparkBio, Pohang City, Pohang City Council, and Pohang Global Enterprise Innovation Park. https://lnkd.in/gJei56in

SDBN Feed: Multiomics startup Pleno raises $25M for commercial launch, plucks new CEO from Illumina https://lnkd.in/g5TD-E_A Pleno has plenty to talk about. The multiomics diagnostic startup has raised $25 million ahead of plans to launch its sequencing instrument early next year, and it’s also tapped a new CEO to lead its [...]

SDBN Trending News: Multiomics startup Pleno raises $25M for commercial launch, plucks new CEO from Illumina https://lnkd.in/gu4zqqVH Pleno has plenty to talk about. The multiomics diagnostic startup has raised $25 million ahead of plans to launch its sequencing instrument early next year, and it’s also tapped a new CEO to lead its [...]

Xaira Launches with a Massive $1 Billion, Says It’s ‘Ready’ to Start Developing Drugs Advances in generative AI have taken the tech world by storm. Biotech investors are making a big bet that similar computational methods could revolutionize drug discovery. This week, ARCH Venture Partners and Foresite Labs, an affiliate of Foresite Capital, announced that they incubated Xaira Therapeutics and funded the AI biotech with $1 billion. Other investors in the new company, which has been operating in stealth mode for about six months, include F-Prime, NEA, Sequoia Capital, Lux Capital, Lightspeed Venture Partners, Menlo Ventures, Two Sigma Ventures and SV Angel. Xaira’s CEO Marc Tessier-Lavigne, a former Stanford president and chief scientific officer at Genentech, says the company is ready to start developing drugs that were impossible to make without recent breakthroughs in AI. https://lnkd.in/d-5chWZ8 #aspenalert #biotech #bioprocess

The Endpoints News 11 list of the most promising biotech startups is out! Congratulations to NEA-backed companies Xaira Therapeutics and Cardurion Pharmaceuticals, who are recognized among the biggest bets, most interesting science and technology, and strongest leadership teams in the industry. 👏🏽 Details and full list here: https://lnkd.in/ejtXNpUQ #biotech #startups

MassBioDrive harnesses the power of MassBio’s global life sciences network to help new founders launch their biotech startups. We announced our #MassBioDrive Fall 2024 Cohort last month, and are highlighting our five emerging biotech companies chosen to participate. Today, please meet D2B3! Q: Tell us about your company and what you’re developing. What are you most excited about? A: D2B3 is a recent spinout from Yale University that aims to revolutionize Drug Delivery (D2) across the Blood-Brain Barrier (B3). D2B3 is developing an antibody asset that transiently relaxes the blood brain barrier to allow delivery of drugs to the brain in a safe and efficient way. We are particularly excited about the versatility of our approach: We can deliver a broad range of drug molecules to the brain with ease; including small molecules, oligonucleotides and even some proteins without the need for conjugation, which often alters the properties of the drug one tries to deliver - it’s truly plug-and-play! Q: What advice do you have for other biotech companies just getting started? A: Assemble a strong team with complementary skills: It is not your job to know everything or solve every problem alone - but it is your job to assemble the right team that does! Also, a biotech startup is long journey with ups and downs and the right team can help each other overcome challenges and afterwards celebrate their victories together. Q: What has been most impactful or surprising to you since joining the MassBioDrive program? A: MassBioDrive offers tailored programming designed to meet the specific needs of early-stage biotech companies, along with direct, personalized mentorship from experienced industry professionals. D2B3 has benefited significantly from this structured and comprehensive program, which has provided support across multiple areas—from refining corporate strategy and prioritizing pipeline development, to receiving detailed, expert feedback on the design of individual studies. Learn more about D2B3: https://lnkd.in/eHGWuQ6b Learn more about MassBioDrive: https://lnkd.in/eGegQGcX Manuel Mohr

ZipBio, a New Seattle Biotech Startup Aiming to Compress Proteins, Raises $4M https://lnkd.in/gWdSUDsj Seattle-based biotech startup ZipBio announced its official launch and revealed $4 million in a seed funding round led by NFX. ZipBio, founded in 2023, is developing a platform that “compresses complex biological structures into smaller, more efficient de novo-designed proteins that retain full functionality, optimizing delivery and therapeutic effectiveness,” according to the company. The company uses generative AI to transform the development of new therapeutics that address some of the most critical unmet needs in healthcare. By creating de novo genes and proteins, ZipBio distills multiple complex functions into compact highly effective therapeutic molecules. The post ZipBio, a New Seattle Biotech Startup Aiming to Compress Proteins, Raises $4M appeared first on Life Science Washington . Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks